Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» semaglutide
semaglutide
Novo builds heart failure case for semaglutide
BioPharma Dive
Fri, 08/30/24 - 11:31 am
Novo Nordisk
obesity
semaglutide
cardiovascular disease
Medicare Coverage of Novo’s Semaglutide for CVD Could Cost $145B Annually: Study
BioSpace
Tue, 08/27/24 - 11:32 am
Novo Nordisk
cardiovascular disease
Medicare
semaglutide
Wegovy
Ozempic
Novo Nordisk plots 2024 FDA filing for once-weekly insulin and semaglutide combo
Fierce Pharma
Mon, 08/12/24 - 06:01 pm
Novo Nordisk
FDA
insulin
semaglutide
Icosema
Weight loss drug could reduce heart attack risk by 20%, study finds
The Guardian, UK
Tue, 05/14/24 - 11:51 am
Novo Nordisk
Ozempic
Wegovy
heart attack
semaglutide
Novo Ends Semaglutide Kidney Study Early Due to Strong Efficacy Signals
BioSpace
Wed, 10/11/23 - 10:15 am
Novo Nordisk
semaglutide
clinical trials
diabetes
chronic kidney disease
Inside the FDA's Form 483 findings at Novo Nordisk's North Carolina semaglutide plant
Fierce Pharma
Tue, 09/19/23 - 10:19 pm
Novo Nordisk
FDA
drug manufacturing
semaglutide
North Carolina
After treatment with semaglutide, people with newly diagnosed type 1 diabetes needed little or no insulin
Medical News Today
Sun, 09/10/23 - 08:03 pm
Novo Nordisk
Ozempic
semaglutide
type 1 diabetes
Obesity: Six trials to watch over the next 12 months
Clinical Trials Arena
Fri, 06/30/23 - 11:45 am
obesity
clinical trials
Novo Nordisk
Altimmune
Innovent Biologics
Pfizer
Shionogi
Tonix
semaglutide
oxytocin
permvidutide
mazdutide
danuglipron
Novo Nordisk says EMA raised safety signal on drugs including semaglutide
Yahoo/Reuters
Thu, 06/22/23 - 10:21 am
Novo Nordisk
EMA
semaglutide
Ozempic
Wegovy
thyroid cancer
obesity
diabetes
Eli Lilly's Mounjaro is primed to surpass Novo Nordisk's popular diabetes and obesity duo: report
Fierce Pharma
Mon, 06/19/23 - 10:29 am
Eli Lilly
Novo Nordisk
Mounjaro
semaglutide
diabetes
obesity
Novo Nordisk’s trial of oral semaglutide meets primary endpoint
Clinical Trials Arena
Tue, 05/23/23 - 09:56 am
Novo Nordisk
semaglutide
oral semaglutide
clinical trials
weight loss
Novo Nordisk's GLP-1 for Type II diabetes approved for first-line treatment
Endpoints
Fri, 01/13/23 - 11:10 am
Novo Nordisk
Rybelsus
semaglutide
FDA
type 2 diabetes
diabetes
A pharmaceutical jack of all trades? Novo CEO touts semaglutide's potential in NASH, Alzheimer's and its hot start in obesity
Fierce Pharma
Mon, 08/29/22 - 10:40 am
Novo Nordisk
semaglutide
NASH
Alzheimer's disease
Saxenda
obesity
Novo Nordisk successfully completes phase 2 trial with CagriSema in people with type 2 diabetes
Yahoo Finance
Mon, 08/22/22 - 10:00 am
Novo Nordisk
clinical trials
CagriSema
semaglutide
diabetes
type 2 diabetes
After phase 2 flop, Novo Nordisk says its NASH work is 'still very much on track'
Fierce Pharma
Wed, 06/29/22 - 05:43 pm
Novo Nordisk
NASH
semaglutide
Novo Nordisk, armed with Wegovy green light, preps aggressive push to build obesity market
Fierce Pharma
Tue, 06/8/21 - 12:21 pm
Novo Nordisk
obesity
drug launches
Wegovy
semaglutide
Novo Nordisk's semaglutide set to tackle obesity with hotly-anticipated FDA green light
Fierce Pharma
Sat, 06/5/21 - 02:26 pm
Novo Nordisk
semaglutide
obesity
FDA
Go or no go? Aducanumab’s day of reckoning
EP Vantage
Thu, 05/27/21 - 10:56 am
Biogen
FDA
aducanumab
Ascendis Pharma
Novo Nordisk
TransCon hGH
semaglutide
Novo Nordisk to launch PhIII obesity trial for oral semaglutide
Endpoints
Wed, 04/21/21 - 11:17 pm
Novo Nordisk
diabetes
obesity
semaglutide
oral semaglutide
clinical trials
FDA Asks Novo Nordisk For More Information On Semaglutide Label Expansion Application
Benzinga
Tue, 03/23/21 - 10:25 am
Novo Nordisk
FDA
diabetes
semaglutide
RTF letters
Pages
1
2
3
4
next ›
last »